Lifecore Biomedical, Inc. De annual debt-to-ebitda ratio
2011
2012
2013
2014
2015
2017
2018
2019
2021
2022
2025
Lifecore Biomedical, Inc. De Debt-to-EBITDA Ratio Growth & History (LFCR)
Lifecore Biomedical, Inc. De's debt-to-ebitda ratio was 30.52 for fiscal 2025.
View full Lifecore Biomedical, Inc. De company overviewLifecore Biomedical, Inc. De annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | 30.52 | — | — |
| 2022 | 2022-05-29 | 2.49 | −14.93 | −85.71% |
| 2021 | 2021-05-30 | 17.42 | — | — |
| 2019 | 2019-05-26 | 4.86 | 3.09 | +174.51% |
| 2018 | 2018-05-27 | 1.77 | −0.24 | −12.09% |
| 2017 | 2017-05-28 | 2.01 | — | — |
| 2015 | 2015-05-31 | 1.66 | 0.41 | +32.19% |
| 2014 | 2014-05-25 | 1.26 | 0.01 | +0.46% |
| 2013 | 2013-05-28 | 1.25 | −1.09 | −46.51% |
| 2012 | 2012-05-27 | 2.34 | 0.86 | +57.65% |
| 2011 | 2011-05-29 | 1.49 | — | — |
Lifecore Biomedical, Inc. De quarterly debt-to-ebitda ratio
Q4.12
Q2.13
Q3.13
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.99 | — | — |
| Q1 2023 | 2022-08-28 | 15.15 | 8.02 | +112.65% |
| Q4 2022 | 2022-05-29 | 2.49 | −14.93 | −85.71% |
| Q3 2022 | 2022-02-27 | 8.20 | −5.96 | −42.11% |
| Q2 2022 | 2021-11-28 | 5.95 | — | — |
| Q1 2022 | 2021-08-29 | 7.12 | — | — |
| Q4 2021 | 2021-05-30 | 17.42 | — | — |
| Q3 2021 | 2021-02-28 | 14.16 | — | — |
| Q2 2020 | 2019-11-24 | 11.75 | 9.96 | +555.94% |
| Q1 2020 | 2019-08-25 | 7.14 | 5.22 | +271.09% |
| Q4 2019 | 2019-05-26 | 4.86 | 3.09 | +174.51% |
| Q3 2019 | 2019-02-24 | 4.13 | 1.66 | +66.93% |
| Q2 2019 | 2018-11-25 | 1.79 | −0.70 | −28.03% |
| Q1 2019 | 2018-08-26 | 1.93 | −0.24 | −10.92% |
| Q4 2018 | 2018-05-27 | 1.77 | −0.24 | −12.09% |
| Q3 2018 | 2018-02-25 | 2.48 | 0.74 | +42.47% |
| Q2 2018 | 2017-11-26 | 2.49 | — | — |
| Q1 2018 | 2017-08-27 | 2.16 | — | — |
| Q4 2017 | 2017-05-28 | 2.01 | — | — |
| Q3 2017 | 2017-02-26 | 1.74 | — | — |
| Q2 2016 | 2015-11-29 | 1.86 | 0.41 | +28.61% |
| Q1 2016 | 2015-08-30 | 1.52 | 0.12 | +8.59% |
| Q4 2015 | 2015-05-31 | 1.66 | 0.41 | +32.19% |
| Q3 2015 | 2015-03-01 | 1.65 | — | — |
| Q2 2015 | 2014-11-30 | 1.45 | — | — |
| Q1 2015 | 2014-08-31 | 1.40 | — | — |
| Q4 2014 | 2014-05-25 | 1.26 | — | — |
| Q3 2013 | 2013-02-24 | 1.37 | — | — |
| Q2 2013 | 2012-11-25 | 1.57 | — | — |
| Q4 2012 | 2012-05-27 | 2.34 | — | — |
Lifecore Biomedical, Inc. De debt-to-ebitda ratio trends
Between the periods ended 2011-05-29 and 2025-12-31, Lifecore Biomedical, Inc. De's debt-to-ebitda ratio increased from 1.49 to 30.52, a change of 29.04. The latest reported quarter, Q2 2026, shows 21.99.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lifecore Biomedical, Inc. De source filings ↗